423 related articles for article (PubMed ID: 26801064)
1. Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles.
Salverda ML; Meinderts SM; Hamstra HJ; Wagemakers A; Hovius JW; van der Ark A; Stork M; van der Ley P
Vaccine; 2016 Feb; 34(8):1025-33. PubMed ID: 26801064
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis.
Klouwens MJ; Salverda MLM; Trentelman JJ; Ersoz JI; Wagemakers A; Gerritzen MJH; van der Ley PA; Hovius JW
Vaccine; 2021 Apr; 39(18):2561-2567. PubMed ID: 33812741
[TBL] [Abstract][Full Text] [Related]
3. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification.
Gerritzen MJH; Salverda MLM; Martens DE; Wijffels RH; Stork M
Vaccine; 2019 Nov; 37(47):6978-6986. PubMed ID: 31383485
[TBL] [Abstract][Full Text] [Related]
4. Engineered Bacterial Outer Membrane Vesicles with Lipidated Heterologous Antigen as an Adjuvant-Free Vaccine Platform for Streptococcus suis.
Li Q; Zhou G; Fei X; Tian Y; Wang S; Shi H
Appl Environ Microbiol; 2023 Mar; 89(3):e0204722. PubMed ID: 36809058
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
6. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.
Hou VC; Koeberling O; Welsch JA; Granoff DM
J Infect Dis; 2005 Aug; 192(4):580-90. PubMed ID: 16028126
[TBL] [Abstract][Full Text] [Related]
7. Bacterial outer membrane vesicles engineered with lipidated antigens as a platform for
Irene C; Fantappiè L; Caproni E; Zerbini F; Anesi A; Tomasi M; Zanella I; Stupia S; Prete S; Valensin S; König E; Frattini L; Gagliardi A; Isaac SJ; Grandi A; Guella G; Grandi G
Proc Natl Acad Sci U S A; 2019 Oct; 116(43):21780-21788. PubMed ID: 31591215
[TBL] [Abstract][Full Text] [Related]
8. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
[TBL] [Abstract][Full Text] [Related]
9. Borrelia burgdorferi outer surface protein (osp) B expression independent of ospA.
Liang FT; Caimano MJ; Radolf JD; Fikrig E
Microb Pathog; 2004 Jul; 37(1):35-40. PubMed ID: 15194158
[TBL] [Abstract][Full Text] [Related]
10. A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.
Beernink PT; Ispasanie E; Lewis LA; Ram S; Moe GR; Granoff DM
J Infect Dis; 2019 Mar; 219(7):1130-1137. PubMed ID: 30346576
[TBL] [Abstract][Full Text] [Related]
11. Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes.
Ma J; Bulger PA; Dante S; Davis DR; Perilli-Palmer B; Coughlin RT
J Infect Dis; 1995 Apr; 171(4):909-15. PubMed ID: 7706819
[TBL] [Abstract][Full Text] [Related]
12. A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.
Nassal M; Skamel C; Kratz PA; Wallich R; Stehle T; Simon MM
Eur J Immunol; 2005 Feb; 35(2):655-65. PubMed ID: 15668917
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
14. Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles.
Zariri A; van Dijken H; Hamstra HJ; van der Flier M; Vidarsson G; van Putten JP; Boog CJ; van den Dobbelsteen G; van der Ley P
Vaccine; 2013 Nov; 31(47):5585-93. PubMed ID: 23933369
[TBL] [Abstract][Full Text] [Related]
15. Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter.
Simon MM; Gern L; Hauser P; Zhong W; Nielsen PJ; Kramer MD; Brenner C; Wallich R
Eur J Immunol; 1996 Dec; 26(12):2831-40. PubMed ID: 8977275
[TBL] [Abstract][Full Text] [Related]
16. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
[TBL] [Abstract][Full Text] [Related]
17. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
18. Protective immunity elicited by rBCG vaccines.
Stover CK; Bansal GP; Langerman S; Hanson MS
Dev Biol Stand; 1994; 82():163-70. PubMed ID: 7958471
[TBL] [Abstract][Full Text] [Related]
19. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
[TBL] [Abstract][Full Text] [Related]
20. A new approach to a Lyme disease vaccine.
Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
